Abstract

Asthma is characterized by hyperresponsivness of tracheobronchial smooth muscles to a variety of stimuli resulting in narrowing of air tubes, often accompanied by increased secretion, mucosal edema and mucus plugging. There is also a disturbing trend of alarming increase in asthma incidences world wide affecting majority of population. . Asthma is treated by Long acting Controller medications like inhaled corticosteroids, beta-2 agonists, mast cell stabilizers, anticholinergics, leukotriene modifiers and Short acting - Reliever medications like beta-2 agonist, oral corticosteroids, anticholinergics. Hence there is a need of a new drug (such as Thromboxane receptor antagonist ) which is therapeutically more efficient than the commonly prescribed medication in management of Asthma. In our study the patients were divided in two groups and prescribed Montelukast and Seratrodast respectively, and their progress was evaluated. We concluded that Seratrodast is more efficient therapeutically than Montelukast in managing Asthma by comparing the FEV1 values and SGRQ scores.